Interestingly, we observed that the inhibition of c-Met through XL-184 (a pharmacological inhibitor of c-Met) markedly increased renal cancer cell apoptosis after sorafenib treatment (Supplementary Fig. 2). Here, MET is linked to renal carcinoma.